&nbsp;

Nov 2024

Drug

capecitabine

Other Name(s): Xeloda®

Quick Link(s):

Jul 2024

Drug

octreotide

Other Name(s): Sandostatin® (multiple brands available) , Sandostatin® LAR™ (Novartis)

Quick Link(s):

Aug 2016

Drug

cyclophosphamide

Other Name(s): Procytox®

Quick Link(s):

Oct 2020

Regimen

CAPE

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Adjuvant, Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2024

Regimen

CAPECISP+TRAS

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

CAPEGEMC

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

gemcitabine,

capecitabine

... Show more tags

Quick Link(s):

Regimen Monograph

Apr 2023

Regimen

CISPDOXOETOPMTTN

Cancer Type:

Endocrine,

Adrenal

Intent: Palliative

Funding:

ODB - General Benefit

mitotane

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2021

Regimen

CRBPPAC+ETOP(PO)

Cancer Type:

Unknown Primary

Intent: Palliative

Funding:

ODB - General Benefit

etoposide - oral capsules

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

Regimen

OCTR

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

octreotide

Drugs Used:

octreotide

... Show more tags

Quick Link(s):

Regimen Monograph

Jun 2024

Regimen

CVP(PO)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

ODB - General Benefit

cyclophosphamide - oral tablets

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jul 2019

Regimen

CVP+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used: